Evidence map›Paper›PMID 26000020›Full record

ArticleStem cells international2015

Human Mesenchymal Stromal Cells Transplantation May Enhance or Inhibit 4T1 Murine Breast Adenocarcinoma through Different Approaches.

T Jazedje, A L Ribeiro, M Pellati, H M de Siqueira Bueno, G Nagata, M Trierveiler, E G Rodrigues, M Zatz

Open access · goldAbstract read
In one paragraph

Article in Stem cells international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

T JazedjeHuman Genome and Stem-Cell Center (HUG-CELL), Institute of Bioscience, University of São Paulo, 05508-090 São Paulo, SP, Brazil ; Laboratory of Cancer Immunobiology, Department of Microbiology, Immunology and Parasitology, Paulista School of Medicine, Federal University of São Paulo (EPM-UNIFESP), 04023-062 São Paulo, SP, Brazil.
A L RibeiroLaboratory of Cancer Immunobiology, Department of Microbiology, Immunology and Parasitology, Paulista School of Medicine, Federal University of São Paulo (EPM-UNIFESP), 04023-062 São Paulo, SP, Brazil.
M PellatiHuman Genome and Stem-Cell Center (HUG-CELL), Institute of Bioscience, University of São Paulo, 05508-090 São Paulo, SP, Brazil.
H M de Siqueira BuenoHuman Genome and Stem-Cell Center (HUG-CELL), Institute of Bioscience, University of São Paulo, 05508-090 São Paulo, SP, Brazil.
G NagataStomatology Department, Faculty of Dentistry, University of São Paulo, 05508-000 São Paulo, SP, Brazil.
M TrierveilerStomatology Department, Faculty of Dentistry, University of São Paulo, 05508-000 São Paulo, SP, Brazil.
E G RodriguesLaboratory of Cancer Immunobiology, Department of Microbiology, Immunology and Parasitology, Paulista School of Medicine, Federal University of São Paulo (EPM-UNIFESP), 04023-062 São Paulo, SP, Brazil.
M ZatzHuman Genome and Stem-Cell Center (HUG-CELL), Institute of Bioscience, University of São Paulo, 05508-090 São Paulo, SP, Brazil.
Universidade de São Paulo · BRUniversidade Federal de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of Mesenchymal Stromal Cells (MSCs) aiming to treat cancer has shown very contradictory results. In an attempt to clarify the contradictory results reported in the literature and the possible role of human fallopian tube Mesenchymal Stromal Cells (htMSCs) against breast cancer, the aim of this study was to evaluate the clinical effect of htMSCs in murine mammary adenocarcinoma using two different approaches: (1) coinjections of htMSCs and 4T1 murine tumor cell lineage and (2) injections of htMSCs in mice at the initial stage of mammary adenocarcinoma development. Coinjected animals had a more severe course of the disease and a reduced survival, while tumor-bearing animals treated with 2 intraperitoneal injections of 10(6) htMSCs showed significantly reduced tumor growth and increased lifespan as compared with control animals. Coculture of htMSCs and 4T1 tumor cells revealed an increase in IL-8 and MCP-1 and decreased VEGF production. For the first time, we show that MSCs isolated from a single source and donor when injected in the same animal model and tumor can lead to opposite results depending on the experimental protocol. Also, our results demonstrated that htMSCs can have an inhibitory effect on the development of murine mammary adenocarcinoma.

Identifiers

PMID26000020
PMCPMC4427122
OpenAlexW2023631556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.